[Use of methisazone for prevention of postvaccinal complications after smallpox vaccination].
D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D003872:Dermatitis / Q000150:complications; D004485:Eczema / Q000150:complications / Q000209:etiology / Q000517:prevention & control; D004673:Encephalomyelitis, Acute Disseminated / Q000517:prevention & control*; D006801:Humans; D007057:Ichthyosis / Q000150:complications; D007211:Indoles / Q000627:therapeutic use*; D007223:Infant; D007732:Kwashiorkor / Q000150:complications; D010392:Pemphigus / Q000150:complications; D011565:Psoriasis / Q000150:complications; D012871:Skin Diseases / Q000150:complications; D012883:Skin Ulcer / Q000150:complications; D012899:Smallpox / Q000150:complications* / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000009:adverse effects*; D013882:Thiosemicarbazones / Q000627:therapeutic use*; D014007:Tinea Favosa / Q000150:complications; D014611:Vaccination; D015001:Yaws / Q000150:complications
D007211:Indoles; D012900:Smallpox Vaccine; D013882:Thiosemicarbazones
Primenenie metisazona dlia profilaktiki postvaktsinal'nykh oslozhneniĭ, vonikaiushchikh pri privivkakh protiv natural'noĭ ospy